Latest Kalaris Therapeutics News & Updates

See the latest news and media coverage for Kalaris Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Kalaris Therapeutics

Clinical-stage biopharmaceutical company developing retinal disease treatments

kalaristx.com
Company type
Private company
Number of employees
2–20

Latest news about Kalaris Therapeutics

Company announcements

  • Kalaris Therapeutics

    Kalaris reports 2025 financial results

    Cash stands at $118M, funding operations to Q4 2027. Positive Phase 1a data for TH103 reported; Phase 1b/2 data expected 1H 2027. $50M private placement completed.

  • Kalaris Therapeutics

    Kalaris Therapeutics presents positive Phase 1 data for TH103

    Dean Eliott, M.D., details safety, tolerability, pharmacokinetics, and early efficacy at the Macula Society meeting.

  • Kalaris Therapeutics

    Kalaris presents Phase 1 data for TH103

    Data on safety, tolerability, pharmacokinetics, and early efficacy in neovascular AMD patients will be presented at the Macula Society Annual Meeting on February 26, 2026.

  • Kalaris Therapeutics

    Kalaris Therapeutics announces oversubscribed $50 million private placement

    The placement involves selling 4.2 million common shares and pre-funded warrants to institutional investors. Proceeds will fund TH103 development for neovascular AMD into Q3 2027.

Unlock all announcements with a

Media coverage

Unlock all articles with a

Never miss news about Kalaris Therapeutics

Track Kalaris Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Kalaris Therapeutics competitors & trending companies

Browse news for competitors to Kalaris Therapeutics and other trending companies.